Cutaxyl 150 150mg/ml 10ml Vial by Kalpa Pharmaceuticals

Usage

1. Verify legal status in your country before sourcing: Testosterone Propionate, Trenbolone Acetate, and Drostanolone Propionate are each controlled substances; confirm Schedule classification and possession rules in your specific jurisdiction.
2. Check SERM availability before beginning the cycle: Tamoxifen and clomiphene are prescription-only in several jurisdictions — procure your PCT agents legally and in advance, not retroactively after the cycle ends.
3. Prepare the injection site and vial aseptically: swab the rubber stopper with 70% isopropyl alcohol; allow to dry fully before drawing. Use a clean, sterile syringe for each draw.
4. Administer subcutaneously or intramuscularly every other day (EOD): rotate injection sites across the glutes, vastus lateralis, or deltoid; 150mg/ml concentration at standard volumes (0.5–1ml) is manageable for most experienced users.
5. Log injection dates and doses to calculate your PCT start date: because all three esters are short-acting, the 3–5 day post-injection clearance window is predictable — but only if your last injection date is precisely recorded.
6. Initiate PCT on schedule and complete the full SERM protocol: do not abbreviate PCT based on subjective recovery; complete the full 4–6 week course, tapering the SERM in the final two weeks to allow endogenous testosterone to stabilise progressively.

Warnings

Frequently asked questions

What is the legal status of Cutaxyl 150's three active compounds in the United States?

All three compounds — Testosterone Propionate, Trenbolone Acetate, and Drostanolone Propionate — are Schedule III controlled substances under the US Controlled Substances Act. Trenbolone Acetate carries an additional restriction: it has no FDA approval for human use whatsoever, existing only as a veterinary compound in the US market. Possession without a valid prescription is a federal offence for all three.

How does the legal classification of this blend differ between the UK and Canada?

In the UK, all three active ingredients are Class C controlled substances under the Misuse of Drugs Act 1971; personal importation carries criminal penalties. In Canada, they fall under Schedule IV of the Controlled Drugs and Substances Act. Neither country approves Trenbolone Acetate for human clinical use. Users must independently verify current enforcement policy and possession thresholds in each jurisdiction before acquiring any component of this blend.

Why does SERM availability matter as part of planning a Cutaxyl 150 cycle?

Because Cutaxyl 150 fully suppresses the HPG axis, PCT with a SERM (tamoxifen or clomiphene) is non-negotiable for restoring endogenous testosterone. In several countries, both SERMs are prescription-only medications — meaning they cannot be legally purchased over the counter. Discovering this constraint after a cycle has ended creates a dangerous gap in recovery. SERM sourcing and legal status must be confirmed before the first injection, not after the last.

Is Cutaxyl 150 at 150mg/ml suitable for precise per-injection volume control?

Yes — 150mg/ml is the lowest concentration in this product category, which directly supports precise volumetric dosing. At 0.5ml per injection, the user administers exactly 75mg total active ingredient across the three compounds; at 1ml, exactly 150mg. This makes dose increments straightforward to calculate without complex arithmetic, and injection volumes remain within a comfortable intramuscular range for experienced users using standard 1ml or 2ml syringes.

How should Cutaxyl 150 be stored after the vial has been opened, and how many injections does one vial provide?

After first puncture, store the vial at room temperature (15–25°C), away from direct light and heat; refrigeration is not required but keeps the oil vehicle stable longer. The rubber stopper is rated for repeated puncture under aseptic technique — always swab before each draw. At 1ml per EOD injection, a single 10ml vial provides approximately 10 injection events, covering roughly three weeks of an EOD protocol. (2) angle_used

Manufacturer

Kalpa Pharmaceuticals' approach to packaging and container selection is a deliberate specification decision rather than a logistical default — and for Cutaxyl 150, the 10ml multi-dose vial format reflects a calculated balance between per-injection dosing convenience and batch-level sterility assurance. Vials within Kalpa's injectable androgen range are sealed under inert-gas headspace conditions prior to stopper crimping, reducing oxidative exposure to the oil-phase carrier across the vial's use life. The stopper compound is selected for compatibility with the specific solvent system used in each formulation, a detail that matters particularly in multi-compound blends where co-solvents vary from single-ester products. Each sealed unit exits the production line with a tamper-evident crimp seal; lot-coded labelling links the physical container to the corresponding batch documentation — including the HPLC concentration verification and LAL endotoxin clearance record — accessible through Kalpa's authorised verification channels. This container-to-document traceability chain means the vial in hand can be matched to a specific, dateable production event, not merely a generic batch code with no retrievable supporting record.